- KR₩36tn
- KR₩39tn
- KR₩4tn
Brief: Celltrion Inc To Acquire 50 Billion Won Worth Of Own Shares
Brief: Celltrion Inc Wins 316 Billion Won Order
Brief: Celltrion Inc Q3 Operating Profit 214 Billion Won, Up 28% From Year Earlier
Brief: Celltrion Inc Wins 299 Billion Won Order
Brief: Celltrion Inc Receives S.Korea Approval For Vegzelma, A Biosimilar Anticancer Drug
Brief: Celltrion Inc Receives Final Sales License For Vegzelma, A Biosimilar Anticancer Drug, From Us FDA
Brief: Abpro Finalizes Strategic Partnership With Celltrion For Worldwide Development And Commercialization Of Cancer Treatment Bispecific Antibody
Brief: Celltrion Wins Patent Ruling In Taiwan Related To Its Rheumatoid Arthritis Biosimilar Drug Truxima
Brief: Celltrion Inc Wins 111 Billion Won Order
Brief: Celltrion Inc To Provide 176 Billion Won Worth Of Biosimilar Drugs
Brief: Celltrion Inc To Halt European Clinical Trials For Covid-19 Inhalation Treatment Due To Virus' Rapid Change Into Endemic Status
Brief: Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Agency's Committee
Brief: Celltrion Inc Says High Infliximab Trough Levels Are Associated With Low Risk Of Relapse When Switching To Subcutaneous Infliximab In Patients With Inflammatory Bowel Disease, Suggests New Data Presented At ECCO 2022 Virtual Congress
Brief: Hikma Expands Licensing Agreement With Celltrion For Remsima Subcutaneous Formulation In MENA
EU regulator okays COVID-19 treatments from GSK-Vir and Sobi
U.S. Omicron plan: boosters, free at-home tests, tighter travel rules (updated)
Celltrion signs COVID-19 antibody therapy supply deals with Europe
Brief: Celltrion Receives CHMP Positive Opinion For Regdanvimab
Private S.Korea firms plan $5.4 bln investment to create vaccine hub